Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD) is an uncommon but potentially fatal complication of allogeneic stem cell transplantation. We report here two patients who underwent T cell-depleted mismatched-related stem cell transplantation for hematologic malignancies and required aggressive post-transplant immunosuppression for graft-versus host disease (GVHD). Both patients subsequently developed markedly elevated EBV-DNA titers in association with monoclonal, light chain-restricted B cell populations in the blood. Although immunosuppressive medications were rapidly tapered, neither patient could receive potentially curative therapy with unmanipulated donorderived lymphocyte infusions (DLI) because of the substantial risk of severe GVHD. Therefore, both patients received repeated courses of rituximab, an anti-CD20 monoclonal antibody, in combination with irradiated DLI. This therapeutic strategy resulted in normalization of the elevated EBV-DNA titers and disappearance of the monoclonal B cell populations. Our results suggest that rituximab and possibly irradiated DLI played an important role in controlling early EBV-LPD in these two patients and may be an effective alternative therapeutic strategy for patients who develop EBV-LPD post transplant and are unable to receive unmanipulated DLI. Keywords: HLA nonidentical; donor lymphocyte infusion; haploidentical; EBV; lymphoproliferative disease Epstein-Barr virus-associated lymphoproliferation (EBV-LPD) which occurs early after allogeneic transplant is frequently characterized by a fulminant clinical course and a poor response to antiviral and antineoplastic treatment.
specific cytotoxic T lymphocyte (CTL) cell populations [6] [7] [8] have been shown to be effective in treating EBV-LPD, findings that support the central role of defective T cell surveillance in the pathogenesis of this aggressive disorder. 1 However, the former strategy is associated with a substantial risk of graft-versus-host-disease (GVHD), particularly in recipients of HLA-mismatched grafts and the latter strategy is both time-consuming and may be of limited efficacy in patients who require continued immunosuppressive medications for concomitant GVHD. Therefore, alternative therapeutic strategies are required for patients who develop EBV-LPD post transplant and are unable to receive donor leukocyte infusions (DLI) or virus-specific CTLs.
Rituximab (Rituxan; IDEC Pharmaceuticals, San Diego, CA, USA) is a genetically engineered chimeric monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B cells and has anti-tumor efficacy when used in the treatment of CD20-expressing non-Hodgkin's lymphomas. [9] [10] [11] [12] Additionally, irradiation of donor-derived lymphocyte populations might allow retention of immunologic competence in eradicating virally infected cells as well as leukemic cells post transplant while reducing or eliminating their ability to generate GVHD. [13] [14] [15] We report here the successful treatment of two patients who developed EBV-LPD with combined rituximab and irradiated donorderived DLI after mismatched stem cell transplant.
Materials and methods

Quantitative PCR to measure Epstein-Barr virus genome load
Blood was drawn into EDTA-containing tubes and processed on the same day. White blood cells were purified on Ficoll-Hypaque (Amersham Pharmacia Biotech, Piscataway, NJ, USA) gradients and the cells treated with proteinase K (60 mg/ml) (Roche Molecular Biochemicals, Indianapolis, IN, USA). Cell aliquots of 1 ϫ 10 6 were amplified using primers (operons) for the EBV BMLF 1 gene. 16 The 50 l PCR reaction components were supplied by Roche Molecular Biochemicals and included 10ϫ PCR buffer, 1.5 mm MgCl 2 , 0.025 m each of dATP, dCTP, dGTP and dUTP, and 1.0 units of Taq DNA polymerase.
The EBV containing Raji cell line (50 EBV genomes/cell) was used to develop a standard curve. Thermal cycle parameters were 30 s at 94°C, 30 s at 55°C and 1 min at 72°C for 35 cycles in a Perkin-Elmer 9600 thermal cycler (Foster City, CA, USA). The PCR product was hybridized to a probe (10 pm) labeled with the tris (2,2Ј-bipyridine) rutherium II chelate (TBR) electrochemiluminescent label (Baron Biotech, Milford, CT, USA). 16 The hybridized PCR product was quantified using a Perkin-Elmer QPCR 5000. All patient samples were amplified using ␤-globin primers to test for DNA integrity.
Leukocyte collection and transfusion
Leukocytes collected in units of whole blood were obtained from the allogeneic progenitor cell donor when only a small number of T lymphocytes (р1 ϫ 10 6 CD3 ϩ /kg) were required for infusion. The volume of whole blood to be collected was derived by calculating the fraction of lymphocytes binding a fluorescein-conjugated CD3-specific monoclonal antibody (Leu 4; Becton Dickinson, Mountain View, CA, USA) with a FACScan cell sorter (Becton Dickinson). Using standard sterile venipuncture technique, whole blood was collected into a citrate phosphate dextrose adenine-1 phlebotomy bag (PL-146 plastic; Baxter-Fenwal Division, Deerfield, IL, USA). If less than 300 ml of blood was collected, an appropriate amount of anticoagulant (AC) was removed in order to maintain an AC volume:whole blood volume ratio of 1.4:10. Following proper labeling, the product was immediately sampled for microbiologyculture and sensitivity, hematology-CBC/differential and FACScan analysis. The product was irradiated (Gammacell 3000E; Nordion International, Toronto, Canada) according to AABB standards at a dose of 2500 cGy. The irradiated blood was administered fresh through a standard 170 micron RBC filter.
Immunofluorescence staining and flow cytometric analysis
Five ml of EDTA anti-coagulated blood was obtained every 1-3 weeks post transplant for lymphocyte immunophenotyping. Samples were routinely labeled for CD3 ϩ , CD4 ϩ , CD3 ϩ CD8 ϩ , CD16 ϩ CD3 Ϫ , and CD19 ϩ CD20 ϩ , cells and clonality of the B lymphocytes assessed by 'B cell clonal excess analysis' as previously described.
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Consensus primer PCR analysis for Ig gene rearrangement
Blood was drawn into EDTA-containing tubes and processed on the same day. White blood cells were purified on Ficoll-Hypaque (Amersham Pharmacia Biotech) gradients and the cells treated with proteinase K (60 mg/ml) (Roche Molecular Biochemicals). Cell aliquots of 2.5 ϫ 10 6 were amplified using the FR3A and JH primers (Operon, Alameda, CA, USA). 19 The 50 l PCR reaction components were supplied by Roche Molecular Biochemicals (1.5 mm MgCl 2 , 0.025 m each of dATP, dCTP, dGTP and dUTP) and Perkin-Elmer (10ϫ PCR buffer and 1.5 units of TaqGold DNA polymerase). Amplification was carried out in a Perkin-Elmer 9600 thermal cycler and thermal cycle parameters were 30 s at 94°C, 30 s at 55°C and 1 min at 72°C for 35 cycles. The PCR product was electrophoresed on to a 12% polyacrylamide gel. All patient samples were amplified using ␤-globin primers to test for DNA integrity.
Case reports
Patient 1
A 28-year-old male was diagnosed with pre-B acute lymphoblastic leukemia in February 1995 and was treated with conventional systemic and central nervous system therapy. In July 1998 he was found to have a systemic relapse and received re-induction therapy but did not achieve a remission. No HLA-matched sibling (MSD) or unrelated donor (MUD) was identified. The patient received a pretransplant conditioning regimen consisting of 1410 cGy fractionated TBI (days Ϫ10 to Ϫ7), followed by thiotepa 10 mg/kg in two divided doses (day Ϫ6), fludarabine 200 mg/m 2 over 5 days (days Ϫ5 to Ϫ1), antithymocyte globulin (ATG) (ATGAM: Upjohn Company, Kalamazoo, MI, USA) 20 mg/kg over 4 days (days Ϫ5 to Ϫ2), and FK506 0.03 mg/kg/day as a continuous intravenous infusion (days Ϫ10 to Ϫ1). He then received a two antigenmismatched, T cell-depleted (TCD) transplant from his father. TCD of the graft was accomplished by use of a CD34 ϩ /CD3 ϩ positive/negative closed selection system (Baxter Isolex 300i). This TCD methodology resulted in approximately a 4.5 log reduction in T lymphocytes. The patient received Ͻ5 ϫ 10 4 CD3 ϩ cells/kg. No post-transplant GVHD prophylaxis was administered. The early posttransplant course was complicated by grade 3 hyper-acute GVHD involving the skin and gut with onset prior to neutrophil engraftment which occurred on day ϩ9. Although the patient had an initial response to two doses of 500 mg/m 2 methylprednisolone followed by 2 mg/kg/day of prednisone, he experienced a steroid-resistant recurrence on day ϩ38 prompting the addition of FK506 and a 10-day course of ATG with a resultant complete remission. However, he presented to clinic on day ϩ74 with a fever of 39.2°C, tonsillar exudates, an elevated LDH of 537 (nl Ͻ240) and diplopia. Body computerized tomographic (CT) scanning revealed only splenomegaly. Brain magnetic resonance imaging was also normal. A tonsillar biopsy demonstrated a dense EBVϩ polymorphic, lymphohistiocytic infiltration and evaluation of cerebrospinal fluid (CSF) showed a mild lymphocytosis and an elevated protein. Flow cytometric analysis of the blood showed a monoclonal population of lambda-restricted B cells expressing CD20 and monoclonality was confirmed by gene rearrangement studies. Quantitative PCR analysis for EBV-DNA genome load showed a markedly elevated titer (Figure 1) . A diagnosis of EBV-LPD was made and immunosuppressive therapy was withdrawn. Rituximab was administered at 375 mg/kg on days ϩ85 and ϩ92. Irradiated whole blood was given in a volume that contained 1 ϫ 10 6 CD3 ϩ /kg recipient weight on day ϩ92. The correlation between treatment administration and fall in EBV-DNA titer is demonstrated in Figure 1 . This was accompanied by resolution of the previously identified circulating monoclonal B cell population by both immunophenotyping and PCR. The patient developed recurrent skin and gut GVHD on day ϩ99, necessitating treatment with steroids, FK506 and phototherapy. He again developed rising EBV-DNA titers accompanied by a monoclonal, lambda-restricted B cell population which no longer expressed CD20 (Figure 1 ). Rituximab was administered at 375 mg/kg on days ϩ119 and ϩ125 without a resultant decline in EBV-DNA titers. Irradiated whole blood was given in a volume that contained 1 ϫ 10 6 CD3 ϩ /kg recipient weight on days ϩ133 and ϩ140, which resulted in a dramatic decline in EBV-DNA titers. The patient died at day ϩ 162 from respiratory failure in the setting of multiple infections including disseminated Acanthomoeba and CMV. No post-mortem examination was obtained.
Patient 2
A 31-year-old male was diagnosed with chronic phase chronic myelogenous leukemia in May 1992. No MSD or MUD was identified and the patient was treated initially with conventional therapy followed by several experimental treatment regimens. The patient subsequently entered an accelerated phase marked by progressive splenomegaly, hyperleukocytosis, and several new cytogenetic abnormalities. Therefore the patient underwent a two antigenmismatched transplant from his father after receiving a pretransplant preparative regimen and TCD of the graft identical to the first patient described in this report. This patient also did not receive post-transplant GVHD prophylaxis. The early post-transplant course was complicated by grade 2 acute GVHD involving the skin at the time of neutrophil engraftment. Neutrophil engraftment occurred on day ϩ9 post transplant. The patient was treated with two doses of 500 mg/m 2 methylprednisolone followed by 2 mg/kg/day of prednisone, in combination with FK506 and a 10-day course of ATG with a resultant complete remission. He subsequently presented to clinic on day ϩ70 with a fever and an enlarged right anterior cervical lymph node. Body CT scanning revealed only a 1-cm right anterior cervical lymph node. Flow cytometry of a peripheral blood specimen revealed a monoclonal population of kappa-restricted B cells expressing CD20 and monoclonality was confirmed by gene rearrangement studies. Quantitative PCR analysis for EBV-DNA genome load revealed a markedly elevated titer ( Figure 2) . A diagnosis of EBV-LPD was made and immunosuppressive therapy was withdrawn; however, photopheresis therapy was initiated in an attempt to maintain control of GVHD. Rituximab was administered at 375 mg/kg on days ϩ75, ϩ82 and ϩ89. Irradiated whole blood was given in a volume that contained 1 ϫ 10 6 CD3 ϩ /kg recipient weight on day ϩ84. The correlation between treatment administration and fall in EBV-DNA titer is demonstrated in Figure 2 . This was accompanied by resolution of the previously identified circulating monoclonal B cell population. Recurrent GVHD occurred on day ϩ99 and was treated with reinstitution of steroids and FK506 without a resultant increase in EBV-DNA titers or reappearance of the previously identified monoclonal B cell population. The patient is alive at day ϩ290 post transplant but has active chronic GVHD. He is without evidence of active EBV-LPD and PCR testing for bcr-abl is negative.
Discussion
Epstein-Barr virus is an ubiquitous viral infection carried by greater than 90% of the adult population. The virus resides in epithelial cells and B cells of the human host and generally does not cause significant disease in immunocompetent individuals because of control by virus-specific cytotoxic T lymphocytes. EBV-induced proliferation of B cells is recognized by CD8
ϩ , major histocompatibility complex (MHC) class I-restricted, cytotoxic T lymphocytes. 20 These T lymphocytes lyse EBV-infected B cells when viral protein fragments are presented on the cell surface in the context of MHC class I molecules. 20 Allogeneic stem cell transplant recipients must undergo aggressive immunoablation to secure engraftment of a donor stem cell source. Immunologic reconstitution in patients receiving a matched sibling allograft is usually prompt, including EBV-specific CTL populations, and thus uncontrolled proliferation of mature, EBV-infected B cells is quite rare, generally reported as less than 1% in recipients of MSD allografts. 4 However, the rapidly increasing number of patients undergoing related mismatched and MUD transplants has resulted in a significant increase in EBV-LPD. These patients have multiple risk factors for the development of EBV-LPD and have a reported incidence of EBV-LPD as high as 15-25%. 4 The principle reasons for the greatly increased risk of EBV-LPD in these transplant populations appears to be related to more aggressive immunosuppressive strategies employed to secure engraftment, TCD techniques directed at preventing GVHD and anti-T cell antibody therapies used to treat GVHD. These measures contribute to a marked delay in immune reconstitution, particularly in recipients of related mismatched and MUD graft recipients. 4, [21] [22] [23] The two patients reported in this manuscript presented all of the previously described risk factors for the development of post-transplant EBV-LPD. 3, 4, 22, 23 Both patients were recipients of TCD partially mismatched related grafts, had received ATG pretransplant as graft rejection prophylaxis, developed GVHD post transplant and required additional treatment with ATG for the treatment of severe acute GVHD. Although some of the clinical findings in both of these patients could not be definitively identified as being related to an EBV-LPD (diplopia, with a mild CSF lymphocytosis and elevated protein, and tonsillar exudates in patient 1, and an enlarged cervical lymph node in patient 2), they appear to be highly suspicious in the context of more suggestive evidence in both patients, ie fevers in the setting of an extensive negative infectious disease workup, high EBV-DNA titers, and circulating, light chain-restricted monoclonal B cell populations. Elevated EBV-LPD DNA titers have been strongly correlated with the development of post-transplant EBV-LPD in several recent reports. [24] [25] [26] [27] [28] Although EBV-LPD in solid organ transplant recipients may regress following discontinuation of immunosuppressive therapy in combination with acyclovir and, in some cases, chemotherapy, 29,30 similar treatment approaches have been less successful in stem cell allograft patients. [2] [3] [4] 31 Thus far, the most promising results have been observed with cellular immunotherapy. Papadopoulos et al 5 reported that three of five patients with EBV-LPD survived after infusions of unirradiated donor leukocytes. Limited chronic GVHD complicated the post-leukocyte infusion course in all three surviving patients. A more specific approach has been reported by Rooney et al. 32 These investigators generated polyclonal, EBV-specific cytotoxic T cell populations in vitro and administered them to high-risk patients for prophylaxis and, in a few cases, for treatment of EBV-LPD. This therapy was successful in both preventing and treating established EBV-LPD. 7 No patient in this study developed GVHD. However, a major limitation with this treatment strategy is the significant time required to generate adequate CTL populations. In fact, despite the design of the study to use cellular therapy for prophylaxis, 15.5% of the patients had increased EBV-DNA titers at the time of treatment.
A second potential limitation of CTLs in patients with established EBV-LPD is the possibility of clinical deterioration secondary to proliferation of T cells and associated inflammation and necrosis at sites of disease. 7 In the report by Papadopolous et al 5 two patients with pulmonary involvement had rapid deterioration after DLI and died of respiratory failure. Similarly, Rooney et al 7 described one patient who received CTLs for established EBV-LPD affecting the nasopharynx and who subsequently required prolonged mechanical ventilation because of an intense inflammatory response at the tumor site. Thus, while EBVspecific CTLs are undoubtedly effective in established disease, their use in this setting may lead to considerable toxicity. 7 Infusion of unirradiated donor leukocytes was clearly not a viable treatment option for the two patients described in this report given the presence of a two antigen mismatch between the donors and patients, the history of severe acute GVHD in both patients and the occurrence of EBV-LPD in a very early period after transplant. Although EBVspecific CTL administration was a potentially viable treatment option, an anticipated delay of 6-8 weeks for the in vitro generation of these CTLs could have allowed progressive and potentially fatal EBV-LPD. In spite of this time delay, an immediate attempt was made to generate donor-derived virus-specific CTLs in vitro for both patients. In the interim, we decided to employ an alternate treatment strategy to control further B cell proliferation through the administration of rituximab and irradiated donor-derived lymphocytes. Rituximab has been demonstrated to have anti-tumor activity in CD20 expressing B cell lymphomas [9] [10] [11] [12] and a recent letter described tumor regression and normalization of elevated EBV-DNA titers in a patient with a posttransplant EBV-LPD. 33 Because it was unclear how effective rituximab would be in this setting, we also administered irradiated DLI based on evidence that effector function of irradiated T cells is at least temporarily preserved. [13] [14] [15] On this basis we administered repeated courses of rituximab to both of these patients and patient 1 received three transfusions of irradiated DLI while patient 2 received one transfusion of irradiated DLI. Importantly, no untoward toxicities were noted in either patient. Both patients demonstrated rapid resolution of both their clinical disease manifestations as well as progressive declines in EBV-DNA titers. It is important to point out that both patients had a drop in the EBV genome level prior to the administration of DLI. Interestingly, patient 1 subsequently developed rising EBV-DNA titers in the context of a lambda-restricted monoclonal B cell population that no longer expressed CD20. Two recent papers have described down-regulation of CD20 as an escape mechanism when rituximab was used to treat low-grade lymphomas. 34, 35 Because of a lack of other effective therapy and the potential re-emergence of a CD20 ϩ clone, two subsequent doses of rituximab were administered but these were not associated with a decline in EBV-DNA titers. However, with further treatments of irradiated DLI, the EBV-DNA titer returned to very low levels. These results suggest that rituximab alone may be effective in CD20-restricted populations but that irradiated DLI may be beneficial if the EBV-LPD is CD20 negative.
It is important to note that neither of these patients presented with bulky adenopathy and frank lymphoma. Therefore, the utility of this approach in patients with more advanced disease is uncertain. However, a previous report suggests that rituximab may be effective in patients with post-transplant EBV-LPD manifesting gross lymphadenopathy. 33 Patient 1 died of an undefined pulmonary syndrome 3 months after initiation of the above described treatment regimen in the context of disseminated amoebiasis. Patient 2 continues to have undetectable EBV-DNA titers or clinical manifestations of EBV-LPD 8 months after treatment. He still requires a combination of FK-506, low-dose steroids and photopheresis for control of chronic GVHD. Thus, given his need for continued immunosuppression, he would be unlikely to benefit from virus-specific CTLs should his EBV-DNA titer begin to rise.
As data show that EBV lymphoproliferation is at least partly due to an imbalance between T and B cells in the T cell-depleted allograft, negative selection of B cells from the allograft may be an effective strategy to reduce the incidence of EBV-LPD in patients at greatest risk. 36 Rituximab and possibly irradiated DLI should be considered for patients who develop EBV-LPD after allogeneic stem cell transplantation and are unable to receive infusions of unirradiated DLI or virus-specific CTL. This therapy appears to be relatively nontoxic and effective. Furthermore, the ability to follow patients at substantial risk for the development of EBV-LPD with quantitative PCR analysis for EBV DNA genomes may allow for earlier institution of effective treatment strategies such as those described in this paper. [24] [25] [26] [27] [28] 
